Physician profile
David Oh
NPI 1952836553
$14,168.64
in general payments reported to CMS, 2019-2025
15 companies · $81.66 in 2025
The $81.66 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $111 · 2021: $21.75 · 2022: $957 · 2023: $125 · 2024: $13K · 2025: $81.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $12K · Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $12,243.79 |
| Food and Beverage | $835.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $12,523.25 | 2024 | |
| Abbott Laboratories | $382.52 | 2022 | |
| Scilex Pharmaceuticals INC. | $227.11 | 2023-2024 | Ztlido |
| Medtronic, INC. | $168.50 | 2022 | |
| Vertos Medical, INC. | $122.13 | 2022 | |
| Alexion Pharmaceuticals, INC. | $121.95 | 2022 | |
| Relievant Medsystems, INC. | $115.75 | 2022 | |
| Spr Therapeutics, INC | $95.73 | 2024 | Sprint Pns System |
| Merz Pharmaceuticals, LLC | $71.16 | 2023-2025 | Xeomin |
| Vertex Pharmaceuticals Incorporated | $65.14 | 2024-2025 | |
| Nalu Medical, INC. | $58.70 | 2024 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $45.96 | 2022 | |
| Esperion Therapeutics, INC. | $21.75 | 2021 | |
| Pfizer INC. | $19.32 | 2023 | |
| Ermi LLC | $18.84 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.